DOCSLIB.ORG

Collaborative R&D, Co-Development and Licensing Agreement for JAK1/JAK2 Inhibitor and INCB28050 -- Current Agreements

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Collaborative R&D, Co-Development and Licensing Agreement for JAK1/JAK2 Inhibitor and INCB28050 -- Current Agreements Dealdoc Collaborative R&D, co-development and licensing agreement for JAK1/JAK2 inhibitor and INCB28050 Incyte Eli Lilly Dec 21 2009 © 2009-2021, Wildwood Ventures Ltd. All rights reserved. Collaborative R&D, co-development and licensing agreement for JAK1/JAK2 inhibitor and INCB28050 Incyte Companies: Eli Lilly Announcement date: Dec 21 2009 Deal value, US$m: 805.0 : sum of license fee and milestone payments First amendment to collaborative R&D, co-development and licensing Related contracts: agreement for JAK1/JAK2 inhibitor and INCB28050 • Details • Financials • Termsheet • Press Release • Filing Data • Contract Details Announcement date: Dec 21 2009 Start date: Dec 18 2009 Bigpharma Biotech Industry sectors: Drug delivery Pharmaceutical Compound name: Baricitinib/ INCB28050 Asset type: Compound Immunology Therapy areas: Musculoskeletal » Arthritis » Rheumatoid arthritis Drug delivery Technology types: Small molecules Co-development Co-promotion Deal components: Collaborative R&D Licensing Option Stages of development: Phase II Geographic focus: Worldwide Financials Deal value, US$m: 805.0 : sum of license fee and milestone payments Upfront, US$m: 90.0 : license fee 635.0 : based on development, regulatory, and commercialization of compounds 19.0 : triggered by advances into phase IIb clinical trial Milestones, US$m: 11.0 : additional milestone payment triggered by phase II clinical trial milestone 50 : sum of milestone payment triggered by phase III program in 2012 n/d : incremental royalty rate increase across all tiers upto the high Royalty rates, %: twenties on potential future global sales n/d : upper royalty rate on higher sales n/d : Incyte to fund thirty percent of development costs from the initiation Funding, US$m: of a Phase IIb trial © 2009-2021, Wildwood Ventures Ltd. All rights reserved. Termsheet 15 November 2012 Incyte Corporation has earned a $50 million milestone payment from Eli Lilly and Company based on the formal initiation of the rheumatoid arthritis Phase III program for baricitinib, Incyte’s oral JAK1/JAK2 inhibitor, formerly known as INCB28050. The Phase III program is being conducted by Lilly as part of the exclusive worldwide License, Development and Commercialization Agreement for baricitinib. 21 December 2009 Exclusive worldwide license and collaboration agreement for the development and commercialization of JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. Lilly will receive worldwide rights to develop and commercialize INCB28050 as an oral treatment for all inflammatory conditions. Incyte will receive an initial payment of $90 million and up to $665 million in additional development, regulatory, and commercialization milestones, as well as tiered, double-digit royalty payments on future global sales with rates ranging up to twenty percent. Incyte will retain the option to co-develop its JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis beginning at the initiation of Phase IIb development. Incyte would be responsible for funding thirty percent of the associated future global development costs from the initiation of a Phase IIb trial. Incyte would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global sales for compounds and/or indications that Incyte elects to co-develop. Incyte consider exercising a co-development option would be in the second half of 2010. Press Release 15 November 2012 Incyte Corporation (INCY) Wins $50 Million From Eli Lilly and Company (LLY) as RA Drug Enters Phase 3 WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (INCY) announced today that it has earned a $50 million milestone payment from Eli Lilly and Company based on the formal initiation of the rheumatoid arthritis (RA) Phase III program for baricitinib, Incyte’s oral JAK1/JAK2 inhibitor, formerly known as INCB28050. The Phase III program is being conducted by Lilly as part of the exclusive worldwide License, Development and Commercialization Agreement for baricitinib About the Phase III Program Four Phase III RA studies are planned, which will investigate the safety and efficacy of baricitinib 2 mg and 4 mg once daily in patients with active RA who are methotrexate-naive, biologic-naive or biologic-experienced. Patients completing any of the four studies will be eligible for enrollment in a fifth study, a long-term extension. Information about the clinical trials can be viewed at www.clinicaltrials.gov. About Incyte Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs for oncology and inflammation. For additional information on Incyte, please visit the Company’s website at www.incyte.com. 21 December 2009 Incyte Corporation (INCY) Sells Autoimmune Therapies to Eli Lilly and Company (LLY) (JOBS) for up to $755 Million INDIANAPOLIS and WILMINGTON, Del., Dec. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis. Lilly will receive worldwide rights to develop and commercialize INCB28050 as an oral treatment for all inflammatory conditions. In exchange for these rights, Incyte will receive an initial payment of $90 million and is eligible for up to $665 million in additional potential development, regulatory, and commercialization milestones, as well as tiered, double-digit royalty payments on future global sales with rates ranging up to twenty percent if a product is successfully commercialized. © 2009-2021, Wildwood Ventures Ltd. All rights reserved. "This new alliance with Incyte reinforces Lilly's commitment to expand our presence in inflammation and autoimmunity through the development of a new class of oral anti-inflammatory therapies," said Eiry Roberts, M.D. Lilly vice president for autoimmune product development. "We look forward to continuing the development of INCB28050 in RA and initiating additional clinical studies to help address the unmet patient needs from debilitating autoimmune and inflammatory diseases." Incyte will retain the option to co-develop its JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis beginning at the initiation of Phase IIb development. Incyte will retain the option to co-develop its JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis beginning at the initiation of Phase IIb development. Under the agreement if Incyte elects to co-develop any compounds and/or indications, Incyte would be responsible for funding thirty percent of the associated future global development costs from the initiation of a Phase IIb trial. Incyte would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global sales for compounds and/or indications that Incyte elects to co-develop. Incyte expects that the earliest it would consider exercising a co-development option would be in the second half of 2010, concurrent with the potential initiation of a Phase IIb trial with INCB28050. As a result of this transaction, Lilly expects to incur a charge to earnings in the fourth quarter of 2009 of approximately $.05 per share. The company reconfirmed its full-year 2009 earnings-per-share guidance of $3.90 to $4.00 per share on a reported basis, or $4.30 to $4.40 per share on a pro forma non-GAAP basis. About JAK Inhibition There are four known JAK enzymes: JAK1, 2, 3 and TYK2. These enzymes are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in RA patients. Cytokines such as interleukin-6, -12, and -23 signal through the JAK pathway and have been clinically validated as therapeutic targets in inflammatory diseases. Additional JAK-dependent cytokines have also been implicated in a number of inflammatory and autoimmune diseases suggesting that JAK inhibitors may be useful for the treatment of a broad range of inflammatory conditions. About Incyte Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology, inflammation and diabetes. Incyte's most advanced compound, INCB18424, is in Phase III development for myelofibrosis. For additional information on Incyte, visit the Company's web site at www.incyte.com. 6 May 2010 Incyte arthritis drug shows promise, triggers milestone May 6, 2010 (Reuters) - Biotechnology firm Incyte Corp (INCY.O) said data from a mid-stage trial of its experimental rheumatoid arthritis treatment showed the drug was safe and effective. Positive data triggers $30 mln milestone from Eli Lilly. 6 May 2010 Incyte Reports First Quarter 2010 Financial Results Completes patient enrollment for Phase III trials for INCB18424 for myelofibrosis Describes positive top-line Phase II results for INCB28050 for rheumatoid arthritis To receive $30 million from Lilly in connection with a milestone for its JAK1/JAK2 Inhibitor,
Load more

Recommended publications
  • The Genetics of Metabolic Disorders* D
    Postgrad Med J: first published as 10.1136/pgmj.48.558.207 on 1 April 1972. Downloaded from Postgraduate Medical Journal (April 1972) 48, 207-2,11. The genetics of metabolic disorders* D. A. HOPKINSON M.A., M.D. MRC Human Biochemical Genetics Unit, Galton Laboratory, University College London THE first work on the genetics of metabolic disorders tion (Harris, 1970) more than sixty such disorders in Man was of course carried out by that great were listed and further examples are regularly being pioneer Sir Archibald Garrod at the turn of the reported. present century (Garrod, 1902). From a study of the It is interesting to note that there is no one hereditary background of a small series of patients particular aspect of metabolism which seems with a rare disorder, alcaptonuria, he discovered the peculiarly susceptible to genetic variation of this first example of recessive Mendelian inheritance in kind. Nor is there any indication that enzymes Man and with remarkable foresight he suggested catalysing particular types of reaction or utilizing that this unusual condition was an example of specialized cofactors are more prone. On the one 'chemical individuality'-an inborn alteration in the hand we have disorders like acatalasia in which metabolism of tyrosine. He also suggested that other there is a deficiency of catalase, the enzyme res- conditions such as albinism and cystinuria could be ponsible for the simple reaction splitting hydrogen manifestations of inborn changes or defects in meta- peroxide to water and oxygen, and on the other hand bolism. He called them 'freaks' or 'sports' of meta- we have the glycogen diseases in which there are bolism.
    [Show full text]
  • Download Download
    Acta Biomed 2021; Vol. 92, N. 1: e2021169 DOI: 10.23750/abm.v92i1.11345 © Mattioli 1885 Update of adolescent medicine (Editor: Vincenzo De Sanctis) Rare anemias in adolescents Joan-Lluis Vives Corrons, Elena Krishnevskaya Red Blood Cell Pathology and Hematopoietic Disorders (Rare Anaemias Unit) Institute for Leukaemia Research Josep Car- reras (IJC). Badalona (Barcelona) Abstract. Anemia can be the consequence of a single disease or an expression of external factors mainly nutritional deficiencies. Genetic issues are important in the primary care of adolescents because a genetic diagnosis may not be made until adolescence, when the teenager presents with the first signs or symptoms of the condition. This situation is relatively frequent for rare anemias (RA) an important, and relatively heteroge- neous group of rare diseases (RD) where anaemia is the first and most relevant clinical manifestation. RA are characterised by their low prevalence (< 5 cases per 10,000 individuals), and, in some cases, by their complex mechanism. For these reasons, RA are little known, even among health professionals, and patients tend to re- main undiagnosed or misdiagnosed for long periods of time, making impossible to know the prognosis of the disease, or to carry out genetic counselling for future pregnancies. Since this situation is an important cause of anxiety for both adolescent patients and their families, the physician’s knowledge of the natural history of a genetic disease will be the key factor for the anticipatory guidance for diagnosis and clinical follow-up. RA can be due to three primary causes: 1. Bone marrow erythropoietic defects, 2. Excessive destruction of mature red blood cells (hemolysis), and 3.
    [Show full text]
  • Haematological Abnormalities in Mitochondrial Disorders
    Singapore Med J 2015; 56(7): 412-419 Original Article doi: 10.11622/smedj.2015112 Haematological abnormalities in mitochondrial disorders Josef Finsterer1, MD, PhD, Marlies Frank2, MD INTRODUCTION This study aimed to assess the kind of haematological abnormalities that are present in patients with mitochondrial disorders (MIDs) and the frequency of their occurrence. METHODS The blood cell counts of a cohort of patients with syndromic and non-syndromic MIDs were retrospectively reviewed. MIDs were classified as ‘definite’, ‘probable’ or ‘possible’ according to clinical presentation, instrumental findings, immunohistological findings on muscle biopsy, biochemical abnormalities of the respiratory chain and/or the results of genetic studies. Patients who had medical conditions other than MID that account for the haematological abnormalities were excluded. RESULTS A total of 46 patients (‘definite’ = 5; ‘probable’ = 9; ‘possible’ = 32) had haematological abnormalities attributable to MIDs. The most frequent haematological abnormality in patients with MIDs was anaemia. 27 patients had anaemia as their sole haematological problem. Anaemia was associated with thrombopenia (n = 4), thrombocytosis (n = 2), leucopenia (n = 2), and eosinophilia (n = 1). Anaemia was hypochromic and normocytic in 27 patients, hypochromic and microcytic in six patients, hyperchromic and macrocytic in two patients, and normochromic and microcytic in one patient. Among the 46 patients with a mitochondrial haematological abnormality, 78.3% had anaemia, 13.0% had thrombopenia, 8.7% had leucopenia and 8.7% had eosinophilia, alone or in combination with other haematological abnormalities. CONCLUSION MID should be considered if a patient’s abnormal blood cell counts (particularly those associated with anaemia, thrombopenia, leucopenia or eosinophilia) cannot be explained by established causes.
    [Show full text]
  • Chapter 03- Diseases of the Blood and Certain Disorders Involving The
    Chapter 3 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50- D89) Excludes2: autoimmune disease (systemic) NOS (M35.9) certain conditions originating in the perinatal period (P00-P96) complications of pregnancy, childbirth and the puerperium (O00-O9A) congenital malformations, deformations and chromosomal abnormalities (Q00-Q99) endocrine, nutritional and metabolic diseases (E00-E88) human immunodeficiency virus [HIV] disease (B20) injury, poisoning and certain other consequences of external causes (S00-T88) neoplasms (C00-D49) symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94) This chapter contains the following blocks: D50-D53 Nutritional anemias D55-D59 Hemolytic anemias D60-D64 Aplastic and other anemias and other bone marrow failure syndromes D65-D69 Coagulation defects, purpura and other hemorrhagic conditions D70-D77 Other disorders of blood and blood-forming organs D78 Intraoperative and postprocedural complications of the spleen D80-D89 Certain disorders involving the immune mechanism Nutritional anemias (D50-D53) D50 Iron deficiency anemia Includes: asiderotic anemia hypochromic anemia D50.0 Iron deficiency anemia secondary to blood loss (chronic) Posthemorrhagic anemia (chronic) Excludes1: acute posthemorrhagic anemia (D62) congenital anemia from fetal blood loss (P61.3) D50.1 Sideropenic dysphagia Kelly-Paterson syndrome Plummer-Vinson syndrome D50.8 Other iron deficiency anemias Iron deficiency anemia due to inadequate dietary
    [Show full text]
  • Clinical Consequences of Enzyme Deficiencies in the Erythrocyte
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 10, No. 5 Copyright © 1980, Institute for Clinical Science, Inc. Clinical Consequences of Enzyme Deficiencies in the Erythrocyte MICHAEL L. NETZLOFF, M.D. Department of Pediatrics and Human Development, Michigan State University College of Human Medicine, East Lansing, Ml 48824 ABSTRACT The anueleate mature erythrocyte also lacks ribosomes and mitochondria and thus cannot synthesize enzymes or derive energy from the Krebs citric acid cycle. Nevertheless, the red blood cell is metabolically active and contains numerous residual enzymes and their products which are essential for its survival and normal functioning. Enzyme deficiencies in the Embden-Myerhoff glycolytic pathway can result in nonspherocytic hemoly­ tic anemia (NSHA), and some are also associated with neuromuscular or neurologic disorders. Glucose-6-phosphate dehydrogenase deficiency in the hexose monophosphate shunt also results in hemolytic anemia, espe­ cially following exposure to various drugs. Defects in glutathione synthesis and pyrimidine 5'-nucleotidase deficiency also cause NSHA, as does in­ creased adenosine deaminase activity. Glutathione synthetase deficiency which is not limited to the red cell also presents as oxoprolinuria with neurologic signs. All red cell enzyme defects appear as single gene errors, in most cases recessive in inheritance, either autosomal or X-linked. Clinical Consequences of Enzyme tains over 40 different enzymes, many of Deficiencies in the Erythrocyte which are essential for its survival or nor­ mal functioning. The purpose of this re­ Prior to maturity, the nucleated red port is to review some inherited enzyme blood cell (rbc) can perform a variety of deficiencies of the erythrocyte which metabolic functions, including active en­ compromise its viability in the circulation zyme synthesis.
    [Show full text]
  • Hemolytic Anemia with Impaired Hexokinase Activity
    Hemolytic anemia with impaired hexokinase activity Alan S. Keitt J Clin Invest. 1969;48(11):1997-2007. https://doi.org/10.1172/JCI106165. Research Article Analyses of key glycolytic intermediates in freshly drawn red cells from six related individuals suggest that decreased hexokinase activity underlies the hemolytic process in the two members with overt hemolysis. Low red cell glucose 6- phosphate (G6P) was observed not only in the anemic patients but in the presumptive heterozygotes as well and served as a useful marker for the presence of the trait. Hexokinase activity was labile in distilled water hemolysates but was only slightly low when protected by glucose, mercaptoethanol, and ethylenediaminetetraacetate (EDTA). Normal red cell hexokinase was demonstrated to be dependent on glucose for maintenance of activity after heating to 45°C. The cells of the proposita are unable to utilize glucose efficiently at glucose concentrations lower than 0.2 mmole/liter whereas normal cells maintain linear glucose consumption to at least 0.05 mM glucose. These qualitative abnormalities could result from the presence of a mutant hexokinase with an abnormally reactive sulfhydryl group and altered substrate affinity in the red cells of this kindred. Find the latest version: https://jci.me/106165/pdf Hemolytic Anemia with Impaired Hexokinase Activity ALAN S. KErrr From the Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32601 A B S T R A C T Analyses of key glycolytic intermediates cells of a young girl with moderately severe chronic in freshly drawn red cells from six related individuals anemia. Although hexokinase activity was only slightly suggest that decreased hexokinase activity underlies the below the range of normal, a comparison between the hemolytic process in the two members with overt he- activity of red cell hexokinase in the affected proposita molysis.
    [Show full text]
  • Productivity Productivity
    Productivity Productivity A Selection of Publications from Our Current and Previous Fellows 1. Maxwell RR, Egan-Sherry D, Gill JB, Roth ME. Management of chemotherapy-induced febrile neutropenia in pediatric oncology patients: A North American survey of pediatric hematology/oncology and pediatric infectious disease physicians. Pediatr Blood Cancer. 2017 Dec; 64(12) 2. Maxwell RR, Cole PD . Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2017 Jun;12(3):176-186 3. Green NS, Manwani D, Qureshi M, Ireland K, Sinha A, Smaldone AM. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use. Pediatr Blood Cancer. 2016 Dec;63(12):2146-2153. 4. Agarwal A, Morrone K, Bartenstein M, Zhao ZJ, Verma A, Goel S. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β. Stem Cell Investig. 2016 Feb 26;3:5 5. Knapp E, Cohen H, Kutlar A, Ghalie R, Manwani D. Intrapatient variability in fetal hemoglobin measurements over time in sickle cell patients not on fetal hemoglobin inducing agents. Am J Hematol. 2016 Mar;91(3) 6. Figueiredo L, Morrone K, Wei C, Ireland K, Cohen HW, Driscoll C, Manwani D. An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait. Blood Cells Mol Dis. 2017 Jul;66:19-23 7. Khazal S, Polishchuk V, Manwani D, Gallagher PG, Prinzing S, Mahadeo KM, 2016, Allogeneic bone marrow transplantation for treatment of severe hemolytic anemia attributable to hexokinase deficiency.
    [Show full text]
  • Non-Commercial Use Only
    Thalassemia Reports 2013; volume 3(s1):e33 Diagnosis and epidemiology of red blood cell enzyme disorders Richard Van Wijk Associate professor, Laboratory For Red Blood Cell Research, Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands The red blood cell possess an active metabolic machinery that pro- tion of fava beans. Patients with uncommon, functionally very severe, vides the cell with energy to pump ions against electrochemical gradi- genetic variants of G6PD experience chronic hemolysis, a disorder ents, to maintain its shape, to keep hemoglobin iron in the reduced designated hereditary nonspherocytic hemolytic anemia (HNSHA).(3) (ferrous) form, and to maintain enzyme and hemoglobin sulfhydryl Hereditary nonspherocytic hemolytic anemia also occurs as a conse- groups. The main source of metabolic energy comes from glucose. quence of other enzyme deficiencies, the most common of which is Glucose is metabolized through the glycolytic pathway and through the pyruvate kinase (PK) deficiency.(4-6) Deficiencies of glucosephos- hexose monophosphate shunt. Glycolysis catabolizes glucose to pyru- phate isomerase(6), triosephosphate isomerase(7), and pyrimidine 52 vate and lactate, which represent the end products of glucose metabo- -nucleotidase deficiency(8) are included among the relatively rare lism in the erythrocyte. Adenosine diphosphate (ADP) is phosphorylat- causes of HNSHA. In the case of some deficiencies, notably those of ed to adenosine triphosphate (ATP), and nicotinamide adenine dinu- glutathione synthetase(9), triosephosphate isomerase(7), and phos- cleotide (NAD)+ is reduced to NADH in glycolysis. 2,3- phoglycerate kinase(10), the defect is expressed throughout the body, Bisphosphoglycerate, an important regulator of the oxygen affinity of and neurologic and other defects may be a prominent part of the clin- hemoglobin, is generated during glycolysis by the Rapoport-Luebering ical syndrome.
    [Show full text]
  • 2 . . Dyserythropoiesis, Refractory
    f . .- RE? osmw DOE-FORRESTAL MARKEY FILES COLLECTI~ Box No. e;*..,+- .._?.,:'2.. Dyserythropoiesis, Refractory 'Anenlia, and "Preleuliernia :" L. .: . ..,I. .',.., ~:*.!.:, Metabolic Features of the Erythrocytes ,,...... ';r ';r t . ' By William N. Valentine, Patricia-. N. Konrad, and Donald E. Paglia j-?- * Twenty-one enzymatic activities and red relatively or absolutely low and somelimes cell glutathione contentr..ar.c ,compared .in , , drarnaticalJy,so. El\ryme ratios were grossly cord blood, dyserythropoietic disorders, aberrant. Capricious. very high individual normal subjects. and subjects with hemo- aclivities occurred in some instances. The lytic syndromes and reticulocytosis ap- heterogeneous nalure of case material, proximating that of the, newborn. The including both hereditary and acquired syn- dysery!hropoietic states are heterogeneous dromes, renders it difficult to interpret and include several hereditary disorders, similarities often seen from case lo case "prgewse-Eic- a@ overt .!e~kemL?: refrac- and somelimes to cord blood patterns on tory anemia with and without marrow the basis of the reversion to fetal erylhro- ringed sideroblasts. and folate deficiency. poiesis as a common denominator. Ralher. Many activities exceeded those of cord the cyto- and karyokirletic abnormalities erythrocytes and "high reticulocyte" con- characterizing dyserythropoiesis of diverse trols by one or even several ;standard etiologies may result in exaggerations and deviations. 'The low phosphoglycerate ki- distortions of a normal asynchronism in ..:-'... nase and glulalhione peroxidase and rela; loss of functional genetic material govern- ..' tively low ribosophosphate pyrophospho- ing enzyme synthesis as the nucleus de- ' .: kinase and adenine-phosphoribodyl trans- generates and cytoplasmic organelles are : ferase of cord erythrocytes were mimicked lost. Uncommonly. Pyruvate kinase was often ,.
    [Show full text]
  • Frequencies of Glucose 6-Phosphate Dehydrogenase Pyruvate Kinase and Hexokinase Deficiencies in the Basrah Population of Iraq
    SCREENING ELSEVIER Screening 4 (1995) 27-34 Frequencies of glucose 6-phosphate dehydrogenase pyruvate kinase and hexokinase deficiencies in the Basrah population of Iraq Menhel M. Al-Naamaaa, Lamia M. Al-Naama*b, Tagreed A. Al-Saadoonb “Chemistry Department, College of Education, Basrah University, Basrah, Iraq bBiochemistry Department, College of Medicine, Basrah University, Basrah, Iraq Received 3 April 1992; revision received 29 July 1993; accepted 9 January 1995 Abstract Introduction: The frequenciesof enzyme deficienciesthat causehemolytic anemiaamong Iraqi peoplein southernIraq have beenstudied. These hereditary red blood cell enzymesin- clude glucose6-phosphate dehydrogenase (G6PD), pyruvate kinase (PK) and hexokinase (HK). The mostcommon enzyme deficiency is G6PD deficiency, an X-linked recessivetrait. PK deficiency is associatedwith chronic hemolytic anemia, but HK deficiency is a rare autosomalrecessive enzymopathy. Methods: A total of 1497clinically normal neonatesand 1629apparently healthy adults from Iraqi Arab original inhabitantsof Basrahwere studied. Blood samplesobtained from the umbilical cord of the newbornsor by venipuncture from adultswere collected in ACD anticoagulantand storedat 4°C. Erythrocyte G6PD activity was measuredqualitatively by the fluorescentspot test or methemoglobinreduction test and con- firmed quantitatively by spectrophotometricanalysis. PK and HK activities were estimated only quantitatively by spectrophotometry.Results: Only sevenpartially deficient infants out of 506 infants and 343 adults were
    [Show full text]
  • BLOOD RESEARCH June 2017 ARTICLE
    VOLUME 52ㆍNUMBER 2 REVIEW BLOOD RESEARCH June 2017 ARTICLE Diagnostic approaches for inherited hemolytic anemia in the genetic era Yonggoo Kim, Joonhong Park, Myungshin Kim Department of Laboratory Medicine, Catholic Genetic Laboratory Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea p-ISSN 2287-979X / e-ISSN 2288-0011 Abstract https://doi.org/10.5045/br.2017.52.2.84 Inherited hemolytic anemias (IHAs) are genetic diseases that present with anemia Blood Res 2017;52:84-94. due to the increased destruction of circulating abnormal RBCs. The RBC abnor- malities are classified into the three major disorders of membranopathies, hemo- Received on March 8, 2017 globinopathies, and enzymopathies. Traditional diagnosis of IHA has been per- Revised on May 24, 2017 formed via a step-wise process combining clinical and laboratory findings. Accepted on May 25, 2017 Nowadays, the etiology of IHA accounts for germline mutations of the respon- sible genes coding for the structural components of RBCs. Recent advances in molecular technologies, including next-generation sequencing, inspire us to ap- Correspondence to ply these technologies as a first-line approach for the identification of potential Myungshin Kim, M.D., Ph.D. mutations and to determine the novel causative genes in patients with IHAs. We Department of Laboratory Medicine, Seoul herein review the concept and strategy for the genetic diagnosis of IHAs and pro- St. Mary’s Hospital, College of Medicine, vide an overview of the preparations for clinical applications of the new molecular The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, technologies.
    [Show full text]
  • A New Metabolic Muscle Disease Due to Abnormal Hexokinase Activity
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.51.2.250 on 1 February 1988. Downloaded from Journal ofNeurology, Neurosurgery, and Psychiatry 1988;51:250-255 A new metabolic muscle disease due to abnormal hexokinase activity K R POULTON, S NIGHTINGALE From the Midland Centrefor Neurosurgery and Neurology, Smethwick, West Midlands, UK SUMMARY A 34 year old man presented with an 8 year history of mild muscle pain and stiffness on exertion especially in the cold. Clinical examination was normal. Apart from a mild persistent leucocytosis, his routine investigations were normal including creatine kinase activity, electro- myography and nerve conduction studies. An ischaemic exercise test produced a slow and incom- plete rise in lactate. Histological examination showed non-specific myopathic changes in some quadriceps femoris muscle fibres. Investigation of muscle metabolism by spectrofluorometric analysis of muscle enzyme activity and by muscle fibre incubation studies revealed a severe defect in glucose phosphorylation, associated with an electrophoretically abnormal hexokinase. Further metabolic studies suggest that the block in glucose metabolism is by-passed via an enhanced phosphorylation of fructose by the abnormal hexokinase. Protected by copyright. Hexokinase (HK) (ATP: D-hexose-6-phospho- regarded as negligible. However, enzyme mea- transferase: EC 2.7.1.1) has an important role in glu- surements in muscle from patients with the X-linked cose metabolism in skeletal muscle, catalysing the muscular dystrophies (Duchenne
    [Show full text]